HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BHC

Bausch Health Companies Inc. (NYSE)

Healthcare — Drug Manufacturers - Specialty & Generic

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Hold 3.0 / 5 5 analysts
$4.77
$-0.16 (-3.25%)
Target: $7.40 (55.1%)
Sign in to add BHC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.78B
P/E Ratio (TTM)-
Forward P/E1.13
EPS (TTM)$-3.24
Dividend Yield-
Profit Margin-11.47%
Revenue Growth11.70%
ROE-
Debt/Equity-
Recommendation Hold 3.0
Analyst Target$7.40
Analysts5
Indexes NYSE

Technical Indicators

RSI (14)40.4
Beta0.41
SMA 20-
SMA 40-
52-Week High$8.69
52-Week Low$4.57
50-Day Avg$5.30
200-Day Avg$6.02
Avg Volume$2.11M
Volume$1.56M

Performance Analysis

NEUTRAL

BHC presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($4.57), which could present a value opportunity.
~ RSI at 40.4 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 11.7% year-over-year.
- Operating at a loss with -11.5% margin.
~ Wall Street consensus is "Hold" from 5 analysts.
+ Average analyst target of $7.40 implies 55.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 12:59 UTC

Back to Screener Export Report